Abstract: The present disclosure describes an apparatus comprising a first set of inlet ports to connect with a vehicle charging station, the first set of inlet ports configured to receive first power from a vehicle charging station; a second set of inlet ports to connect with an external power source, the second set of inlet ports configured to receive second power from the external power source; a first set of outlet ports to supply the first power from the vehicle charging station to a first vehicle in a first configuration and the second power from the external power source to the first vehicle in a second configuration; and a second set of outlet ports to direct the first power from the vehicle charging station to a second apparatus in the second configuration, wherein the second apparatus is configured to supply the first power to a second vehicle.

Abstract: The present disclosure describes a connector box, comprising a vehicle inlet port configured to receive a vehicle connector configured to connect to a direct current (DC) or alternating current (AC) vehicle charging station; a locking mechanism configured to secure the vehicle connector within the vehicle inlet port, wherein the locking mechanism is configured to be activated upon insertion of the vehicle connector into the vehicle inlet port and remain activated until deactivation by an authorized user; and an outlet port configured to supply electrical power received via the vehicle inlet port and to an apparatus, the apparatus configured to supply the electrical power from the outlet port to a vehicle connected to the apparatus in a vehicle charging session.

Abstract: There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a dithiolsaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods.

Abstract: The invention broadly provides an implantable medical device comprising a liquid rope coil scaffold. The implant may consist essentially of the scaffold, where the scaffold is the implant and pores in the scaffold may incorporates one or more agents (i.e. drugs, growth factors), or the scaffold may comprise only part of the medical device, for example an implant that is partly or fully covered with a layer of the scaffold. The porosity of the scaffold may be tailored to suit the application, for example a porosity that is tailored to hold and release drug or biological molecules in vivo, a porosity to provide a surface roughness that is conducive to promotion of in-vivo bio-integration (for example vascularisation) or prevention of fibrosis, or a porosity that provides structural strength. The scaffold may be essentially tubular, or may be provided as a planar structure, or may be any shape and can be used to coat, fully or partially any shape or size of medical implant.

Abstract: The invention relates to a method of visualising a peripheral nerve, the method comprising contacting the nerve with a 5-aminolevulinate or a derivative thereof.

Abstract: The present invention provides an in vitro method, and in vitro assay, for staging, classification, screening, monitoring, stratification, selecting treatment for, ascertaining whether treatment is working in, and/or prognostication of cancer in a subject comprising determining allelic imbalance and copy number of target gene-regions in tumor DNA from a subject as set out in the application. The present invention also provides a set of oligonucleotide probes and kits for use in the method, and assay, of the present invention.

Abstract: An imaging apparatus for imaging a sample (7) comprises an array of electronically addressable pixels (6) wherein each pixel is arranged to support a surface plasmon resonance therein to generate an evanescent electromagnetic field. This field extends transversely from the pixel so as to be salient from the array at a first side of the array for illuminating the sample at said first side. A light source (15) is arranged to illuminate the array with excitation light therewith to generate said surface plasmon resonance. An optical detector (12A, 12B, 12C) is arranged at a second side of the array which is opposite to said first side of the array for detecting optical radiation returned from the array in response to illumination of the array by said excitation light. A processing unit (4) is arranged to associate the detected optical radiation with the address of the pixel or pixels within the array at which the surface plasmon resonance was generated.

Abstract: The present disclosure relates to a new anti-cancer peptide; a vector encoding same; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said anti-cancer peptide; use of said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine to treat cancer; a method of treating cancer using said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine; and a combination therapeutic for the treatment of cancer comprising said anti-cancer peptide, vector, pharmaceutical composition, immunogenic agent, bispecific or vaccine.

Abstract: Disclosed is a video summarisation method that includes converting an input video file to a video transcript using speech recognition, segmenting the video transcript into a plurality of paragraphs using a transformer based model, performing relevance ranking of the plurality of paragraphs by assigning a paragraph importance score to each paragraph, based on relevance of each paragraph to an overall content of the video transcript, creating a plurality of candidate summaries from the plurality of paragraphs, each candidate summary comprising two or more paragraphs, performing coherence reranking of the plurality of candidate summaries based on a combination of coherence and relevance of each candidate summary, and selecting a summary based on the coherence reranking.

Abstract: According to aspects of embodiments described herein, an optical computing device (100) comprises a plurality of input waveguides (101), a photonic meta-surface (103) in contact with the plurality of input waveguides, and a plurality of output waveguides (105) in contact with the transformational meta-surface. The optical computing device may be configured to perform a mathematical operation may be a matrix multiplication. A computer-implemented method (300) of designing an optical computing device includes a plurality of input waveguides, a photonic meta-surface, and a plurality of output waveguides, the method includes exciting each input waveguide one-by-one (303) and measuring the energy at the input region and the output region (305) to determine a contribution of the current input waveguide. The sum of contributions (307) of all input waveguides are compared to a target transformation (315) to determine a loss value used to update a set of design parameters (317).

Abstract: A method of controlling an electricity distribution network, wherein the electricity distribution network is a mesh network including a plurality of loads and there is a voltage-source converter connected to a point in the network. The method comprises, while using the voltage-source converter to try to hold the voltage magnitude constant at said point, establishing a record of how, at said point, the real power flowing between the network and the voltage-source converter varies with variation of the reactive power that the voltage-source converter causes to flow between itself and the network, using a reactive-power value, proportional to the sum of the reactive-power draws of the loads, in order to look up a real-power value from the record, and configuring the voltage-source converter to supply into the network at said point reactive and real power at said reactive- and real-power values, respectively.

Abstract: The invention relates to an anti-viral composition comprising at least one, and ideally a plurality of, monoclonal antibodies, or fragments thereof; an immunogenic agent, vaccine or pharmaceutical composition comprising the afore anti-viral composition; said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition for use in the treatment of or prevention of a viral infection; use of said anti-viral composition in the manufacture of a medicament to treat or prevent a viral infection; a combination therapeutic for use in the treatment or prevention of a viral infection comprising said anti-viral composition, immunogenic agent, vaccine or pharmaceutical composition in combination with at least one other therapeutic agent; and a method of treating or preventing a viral infection comprising administering said anti-viral composition, immunogenic agent, vaccine or said pharmaceutical composition to an individual having, or suspected of having, a viral infection.

Abstract: The present invention provides a method for performing optical image detection using a camera module comprising a Digital MicroMirror Device, a first point Photo Detector, a second point Photo Detector, a first lens and a second lens.

Abstract: A method for predicting risk of recurrence of cancer in an individual with cancer, the method comprising a step of assaying a cancer sample from the individual for positive expression of at least two genes or proteins encoded by those genes selected from the group consisting of FOXM1, UHRF1, PTTG1, E2F1, MYBL2, HMGB2, ATAD2, E2F8, ZNF367 and TCF19, wherein positive expression of the at least two genes correlates with increased risk of recurrence of cancer compared with an individual who does not exhibit positive expression of the at least two genes or proteins encoded by those genes.

Abstract: The present invention relates to the therapeutic uses of compositions containing antibody molecules and functional fragments thereof, e.g antibody molecules and functional fragments capable of binding to tumor necrosis factor alpha (TNF?), in the topical treatment of inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.

Abstract: There is provided a method for distinguishing between sepsis and systemic inflammatory response syndrome (SIRS) in a patient, comprising: (i) determining the amount of one or more biomarker for sepsis, and one or more biomarker for SIRS in a sample obtained from a patient, wherein the one or more biomarker for sepsis is selected from the group consisting of: ITGB3, ITGA2B, MYL9, LCN2, TREML1, LCN15, CMTM5, PPBP, and PF4; and the one or more biomarker for SIRS is selected from the group consisting of: PLA2G7, ARHGEF10L, MYCL, TGFBI, and GPR124, (ii) comparing the amount of the one or more biomarker for sepsis determined in said sample in (i) to a corresponding reference value representative of a healthy individual, (iii) comparing the amount of the one or more biomarker for SIRS determined in said sample in (i) to a corresponding reference value representative of a healthy individual; wherein the patient is diagnosed as having sepsis, when an increase is observed in the one or more biomarker for sepsis, and no

Abstract: The present disclosure relates to a new T-cell receptor (TCR), in particular at least one complementarity-determining region (CDR) thereof; a T-cell expressing said TCR; a clone expressing said TCR; a vector encoding said TCR; a soluble version of said TCR; a pharmaceutical composition or immunogenic agent or bispecific or vaccine comprising said TCR, said cell, said clone or said vector; said TCR or said cell or said clone or said vector or said pharmaceutical composition or immunogenic agent or bispecific or vaccine for use in the treatment of cancer; a method of treating cancer using said TCR, said cell, said clone, said vector, said pharmaceutical composition, immunogenic agent, bispecific or vaccine comprising said TCR; and a ligand with which said TCR binds.

Abstract: The present invention relates to a cell, wherein the cell is modified to: reduce O-GalNAc galactosylation activity in the cell by reduction of functional COSMC molecular chaperone in the cell and/or by reduction of functional T-synthase in the cell; and overexpress ?1,4-galactosyltransferase in the cell; and associated methods, kits and uses.

Abstract: The invention provides a monolithic integrated mesh device for atomization or pumping of a fluid or liquid comprising a plurality of apertures and a piezoelectric material. The piezoelectric material is bonded to the mesh device at an atomic scale. In one embodiment the monolithic micro-fabricated device of the invention includes piezoelectric material that eliminates the need for expensive assembly process and improves reliability. This also has advantage of requiring lower operating voltage and less complicated circuitry.

Abstract: Serious gaming for interrelated critical infrastructure (CI) resilience improvement includes receiving from a serious gaming participant a selection of an anomalous event for a geographic region for which a hierarchy of CI elements has been modeled, and a specified change in allocation of at least one resource in a corresponding one of the CI elements. A previously determined cascading impact upon the CI elements resulting from the anomalous event is then retrieved and compared to a hypothetical cascading impact produced by a simulation of the model with the specified change. A visualization of the comparison is transmitted to the serious gaming participant so as to show the result of the hypothetical change in resources upon the cascading impact of the event in the hierarchy of CI elements.